Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma.
Kaposi's Sarcoma (KS) is a pathology which occurs with increased frequency and in a particularly aggressive form in AIDS patients. The HIV-1 Tat protein appears to be an important co-factor in the induction of the extensive neo-vascularization associated with AIDS-KS. Tat acts as a chemoattractant for endothelial cells in vitro, inducing both chemotactic and invasive responses. Several clinical trials have been performed testing the effectiveness of diverse biological agents in therapy of KS, among these the type I interferons. Type I IFNs have diverse biological functions besides their anti-viral activity, including anti-angiogenic properties. We have shown that IFN alpha and IFN beta are potent inhibitors of both primary and immortalized endothelial cell migration and morphogenesis in vitro as well as neo-angiogenesis induced by HIV-1 Tat in vivo. The inhibitory effect of IFN class I on HIV-Tat associated angiogenesis further supports its use as a therapy for epidemic Kaposi's sarcoma. The use of recombinant IFNs at the levels required to obtain a therapeutic effect are associated with side effects and toxicity, therefore we are now developing a gene therapy approach for constant and local delivery type I IFNs.
Marchisone
C
C
National Institute for Cancer Research, Advanced Biotechnologies Center, Genova, Italy.
Benelli
R
R
Albini
A
A
Santi
L
L
Noonan
D M
DM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D004730:Endothelium, Vascular / Q000187:drug effects; D015696:Gene Products, tat / Q000502:physiology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D015696:Gene Products, tat; D007370:Interferon Type I